Surveys in which U.S. adults report their current weight have shown that the share of those reporting they weigh 200 pounds or more has increased over the past few decades. In 2024, around 28 percent of respondents reported their weight as 200 pounds or more, compared to 15 percent in 1990. However, the same surveys show the share of respondents who report they are overweight has decreased compared to figures from 1990. What percentage of the U.S. population is obese? Obesity is an increasing problem in the United States that is expected to become worse in the coming decades. As of 2023, around one third of adults in the United States were considered obese. Obesity is slightly more prevalent among women in the United States, and rates of obesity differ greatly by region and state. For example, in West Virginia, around 41 percent of adults are obese, compared to 25 percent in Colorado. However, although Colorado is the state with the lowest prevalence of obesity among adults, a quarter of the adult population being obese is still shockingly high. The health impacts of being obese Obesity increases the risk of developing a number of health conditions including high blood pressure, heart disease, type 2 diabetes, and certain types of cancer. It is no coincidence that the states with the highest rates of hypertension are also among the states with the highest prevalence of obesity. West Virginia currently has the third highest rate of hypertension in the U.S. with 45 percent of adults with the condition. It is also no coincidence that as rates of obesity in the United States have increased so have rates of diabetes. As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, compared to six percent in the year 2000. Obesity can be prevented through a healthy diet and regular exercise, which also increases overall health and longevity.

The adult obesity rate, or the percentage of the county population (age 18 and older*) that is obese, or has a Body Mass Index (BMI) equal to or greater than 30 [kg/m2], is illustrative of a serious health problem, in Champaign County, statewide, and nationally.

The adult obesity rate data shown here spans from Reporting Years (RY) 2015 to 2024. Champaign County’s adult obesity rate fluctuated during this time, peaking in RY 2022. The adult obesity rates for Champaign County, Illinois, and the United States were all above 30% in RY 2024, but the Champaign County rate was lower than the state and national rates. All counties in Illinois had an adult obesity rate above 30% in RY 2024, but Champaign County's rate is one of the lowest among all Illinois counties.

Obesity is a health problem in and of itself, and is commonly known to exacerbate other health problems. It is included in our set of indicators because it can be easily measured and compared between Champaign County and other areas.

This data was sourced from the University of Wisconsin’s Population Health Institute’s and the Robert Wood Johnson Foundation’s County Health Rankings & Roadmaps. Each year’s County Health Rankings uses data from the most recent previous years that data is available. Therefore, the 2024 County Health Rankings (“Reporting Year” in the table) uses data from 2021 (“Data Year” in the table). The survey methodology changed in Reporting Year 2015 for Data Year 2011, which is why the historical data shown here begins at that time. No data is available for Data Year 2018. The County Health Rankings website notes to use caution if comparing RY 2024 data with prior years.

*The percentage of the county population measured for obesity was age 20 and older through Reporting Year 2021, but starting in Reporting Year 2022 the percentage of the county population measured for obesity was age 18 and older.

Source: University of Wisconsin Population Health Institute. County Health Rankings & Roadmaps 2024. www.countyhealthrankings.org.

The prevalence of obesity in the United States has risen gradually over the past decade. As of 2023, around ** percent of the population aged 18 years and older was obese. Obesity is a growing problem in many parts of the world, but is particularly troubling in the United States. Obesity in the United States The states with the highest prevalence of obesity are West Virginia, Mississippi, and Arkansas. As of 2023, a shocking ** percent of the population in West Virginia were obese. The percentage of adults aged 65 years and older who are obese has grown in recent years, compounding health issues that develop with age. Health impacts of obesity Obesity is linked to several negative health impacts including cardiovascular disease, diabetes, and certain types of cancer. Unsurprisingly, the prevalence of diagnosed diabetes has increased in the United States over the years. As of 2022, around *** percent of the population had been diagnosed with diabetes. Some of the most common types of cancers caused by obesity include breast cancer in postmenopausal women, colon and rectum cancer, and corpus and uterus cancer.

Forecast: Prevalence of Overweight Among Male in United States 2024 - 2028 Discover more data with ReportLinker!

Forecast: Prevalence of Obesity Among Women Aged 18 or over in United States 2024 - 2028 Discover more data with ReportLinker!

In 2021, around ** percent of high school students in the state of West Virginia were obese, making it the state with the highest share of obese high school students that year. Colorado and Utah had the lowest obesity rates among students that year. The state with the highest share of obese adults West Virginia not only has the highest rate of obese high school students, it is also the U.S. state with the highest percentage of obese adults, which was about ** percent as of 2023. Obesity remains a growing problem in the United States, especially in the southern states. Body image among college students In the fall of 2024, just over half of U.S. college students (18 years and older) described their weight as “about the right weight”. Over ********* of the respondents stated that they were slightly overweight, while *** percent said they were very overweight. Furthermore, roughly ** percent of college students rated their health as very good, while just ****percent of this group rated their general health as poor.

According to Cognitive Market Research, the global Obesity Intervention Devices market size will be USD 256.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 102.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 76.86 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 58.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 12.81 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 5.12 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
The Gastric Bands Device held the highest Obesity Intervention Devices market revenue share in 2024.

Market Dynamics of Obesity Intervention Devices Market

Key Drivers for Obesity Intervention Devices Market

Rising Obesity Rates to Increase the Demand Globally

Rising obesity rates are driving the obesity intervention devices market due to the increasing need for effective management and treatment solutions. As obesity rates escalate globally, more individuals require medical devices designed to aid in weight loss and management. This growing demand prompts healthcare providers and patients to seek advanced intervention options, such as surgical devices, non-surgical tools, and monitoring systems. The escalating prevalence of obesity-related health conditions, such as diabetes and cardiovascular diseases, further accelerates the need for these devices. In response, the market is expanding to offer innovative solutions that address the urgent need for effective obesity management, supporting the growth of the obesity intervention devices sector.

Growing awareness of obesity-related health risks to Propel Market Growth

Growing awareness of obesity-related health risks is driving the obesity intervention devices market as individuals and healthcare professionals increasingly recognize the serious health implications of obesity. This heightened awareness highlights the need for effective interventions to manage and reduce obesity, leading to a surge in demand for medical devices designed for weight management. As public awareness campaigns, educational programs, and media coverage shed light on the risks associated with obesity—such as diabetes, heart disease, and hypertension—more people are motivated to seek solutions. Consequently, healthcare providers are more likely to recommend advanced obesity intervention devices. This increased focus on prevention and treatment drives the growth of the market, fostering innovation and expanding the range of available obesity management solutions.

Restraint Factor for the Obesity Intervention Devices Market

High Initial Costs to Limit the Sales

High initial costs are restraining the obesity intervention devices market because the substantial investment required for advanced medical devices can limit their accessibility and adoption. These devices often involve complex technology and manufacturing processes, leading to elevated prices. For many patients and healthcare providers, the high cost poses a barrier, particularly in regions with limited healthcare budgets or insurance coverage. This financial constraint can delay or prevent the acquisition and use of such devices, impacting market growth. Additionally, high costs can lead to limited market penetration, especially in low- and middle-income countries where affordability is a significant issue. As a result, the high initial costs of obesity intervention devices can significantly restrict market expansion and adoption.

Impact of Covid-19 on the Obesity Intervention Devices Market

The COVID-19 pandemic impacted the obesity intervention devices market by disrupting supply chains and delaying elective procedures, including those related to obesity treatment. Lockdowns and social distancing measures led to reduced patient visits a...

According to Saudi Arabia's National Health survey in 2024, the highest obesity rate for women was in the age group 65 to 69 with a share of **** percent. In comparison, for men, the highest rate of obesity was **** percent in the age group 60 to 64 years.

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Adults who are not overweight or obese - This indicator shows the percentage of adults who are not overweight or obese. In Maryland in 2015, of adults considered obese, 52% had high blood pressure, 44% had high cholesterol, and 21% had diabetes. Healthy weight can aid in the control of these conditions if they develop. Link to Data Details

In the period 2021 to 2024, Norrbotten County had the highest share of obese adults in Sweden, at over ** percent. A further ** percent of people in Norrbotten were classed as overweight. In the capital Stockholm, ** percent of people were classed as overweight.

Weight loss service providers confront intense competition in a highly saturated and concentrated business environment. Proprietary diet plans have existed for decades, with significant industry players established as far back as the early 1960s. Company performance is influenced by domestic population growth, favorable economic conditions and health factors (obesity rate, healthy eating index). Despite the favorable economic conditions following COVID-19, competition from substitutes has stolen consumers. Industry-wide revenue declined at a CAGR of 2.9% to $3.5 billion, falling 0.1% in 2024 alone. As a result, industry profit declined at a similar rate throughout 2024. COVID-19 spurred consolidation and concentration. Larger firms were able to weather the downturn, and smaller establishments exited. Additionally, COVID-19 changed consumers' attitudes toward remote communications. Even though weight loss services have been traditionally in-person, lockdowns changed attitudes. Platforms and mobile technology enabled consumers to engage with others in new novel ways, changing the need for in-person service. Going forward, the continued emphasis on digital platforms will amplify competitive advantages for the most prominent weight loss service providers, causing many more small-scale companies to exit. Yet, regions like the Southeast with a significant obese population will be better served by larger enterprises that can provide better analytics and sophisticated communication modalities. Dominant enterprises may expand, gaining new revenue streams through acquisitions to better meet out-of-market competition products and services (Fitbit, Smartphone apps, social media groups, VR chat rooms.) Nevertheless, revenue will decline at a CAGR of 0.4% to $3.4 billion through the end of 2029.

The share of the population with overweight in Germany was forecast to continuously increase between 2024 and 2029 by in total 1.4 percentage points. After the fifteenth consecutive increasing year, the overweight population share is estimated to reach 68.88 percent and therefore a new peak in 2029. Notably, the share of the population with overweight of was continuously increasing over the past years.Overweight is defined as a body mass index (BMI) of more than 25.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the share of the population with overweight in countries like Austria and Switzerland.

United States Bariatric Surgery Market size was valued at USD 860.0 Million in 2023 and is projected to reach USD 1402.05 Million by 2031, growing at a CAGR of 6.3% from 2024 to 2031.

Key Market Drivers Rising Prevalence of Severe Obesity Cases: The dramatic increase in severe obesity cases is intensifying the demand for bariatric procedures, with the CDC reporting that 9.2% of American adults had severe obesity in Q4 2023. For instance, in March 2024, Johnson & Johnson's Ethicon division announced the expansion of their bariatric surgery device portfolio to address this growing patient population. Growing Insurance Coverage and Reimbursement Support: Insurance acceptance for bariatric procedures is improving substantially, with the Centers for Medicare & Medicaid Services reporting a 34% increase in bariatric surgery approvals during 2023. For instance, in January 2024, Intuitive Surgical announced its collaboration with major insurers to expand robotics-assisted bariatric surgery coverage. Propelling Technological Advancements in Surgical Techniques: The evolution of surgical technologies is revolutionizing bariatric procedures, with the FDA approving 12 new bariatric surgery devices in 2023. For instance, in February 2024, Stryker Corporation unveiled its advanced laparoscopic system specifically designed for bariatric surgeries. Boosting Market Through Minimally Invasive Alternatives: The shift towards minimally invasive procedures is accelerating market growth, with the American Society for Metabolic and Bariatric Surgery reporting that 95% of bariatric surgeries in 2023 were performed laparoscopically. For instance, in January 2024, Apollo Endosurgery announced the successful trials of their new endoscopic bariatric system.

Introduction

Global Diabetes Drugs Market size is expected to be worth around USD 153.4 Billion by 2033, from USD 69.1 Billion in 2023, growing at a CAGR of 8.6% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 51.3% share with a revenue of US$ 35.4 Million.

Several factors are driving the growth of the diabetes drug market. A key factor is the rising prevalence of diabetes globally, especially type 2 diabetes. Data from the International Diabetes Federation indicates that the number of adults with diabetes is expected to increase from 537 million in 2021 to 783 million by 2045. Furthermore, advancements in diabetes medications, such as the introduction of GLP-1 receptor agonists and SGLT-2 inhibitors, offer effective alternatives to traditional therapies, enhancing market expansion.

Recent developments in the sector include the introduction of new drugs and formulations. For example, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of the popular anti-diabetic drug Liraglutide, in India in January 2024. Additionally, companies like Akums Drugs and Pharmaceuticals have been developing novel combination therapies aimed at improving treatment effectiveness and adherence among the elderly with type 2 diabetes.

Despite these advancements, the market faces challenges such as the high costs associated with diabetes drug therapies, which pose significant barriers, particularly in less developed regions. Nonetheless, the ongoing focus on diabetes care, coupled with increasing awareness and substantial research and development investments by leading companies, are anticipated to maintain the market's growth trajectory. North America leads this market, propelled by high obesity rates and sedentary lifestyles, with the United States holding the largest share due to its significant demand for insulin and other diabetes medications.

This report presents findings from the Government's National Child Measurement Programme (NCMP) for England, 2023/24 school year. It covers children in Reception (aged 4-5 years) and Year 6 (aged 10-11 years) in mainstream state-maintained schools in England. The report contains analyses of Body Mass Index (BMI) classification rates by age, sex, deprivation and ethnicity as well as geographic analyses.

According to Cognitive Market Research, the global Semaglutide market size is USD 112.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 45.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 33.75 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 25.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
The Latin America market will account for more than 5% of global revenue and will be USD 5.63 million in 2024, growing at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.
The Middle East and Africa held the major markets, accounting for around 2% of the global revenue. The market was USD 2.25 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
The hospitals' pharmacies held the highest semaglutide market revenue share in 2024.

Market Dynamics of Semaglutide Market

Key Drivers of Semaglutide Market

Increasing Prevalence of Obesity and Type 2 Diabetes Drives Market Growth

The escalating prevalence of obesity and type 2 diabetes acts as a primary driver for market growth in the healthcare sector. With lifestyle changes, including sedentary habits and unhealthy dietary patterns, becoming more prevalent globally, the incidence of obesity and associated metabolic conditions like type 2 diabetes continues to rise. This surge in disease burden necessitates effective management and treatment solutions, stimulating demand for pharmaceutical interventions such as Semaglutide. As healthcare systems strive to address the challenges posed by these chronic conditions, pharmaceutical companies innovate and develop therapies like Semaglutide to provide patients with better outcomes and improved quality of life, thereby driving market growth in response to the escalating demand.

Advancements in Drug Delivery Systems Propels Market Growth

Advancements in drug delivery systems have emerged as a significant catalyst for market growth within the pharmaceutical industry. Innovative technologies in drug delivery offer several benefits, including improved efficacy, enhanced patient compliance, and reduced side effects. Specifically, developments in delivery mechanisms for medications like Semaglutide have propelled market expansion. Novel formulations such as oral semaglutide represent a milestone in diabetes management, offering patients a non-invasive alternative to injections. Additionally, sustained-release formulations ensure prolonged drug action, optimizing therapeutic outcomes. These advancements address patient preferences and present opportunities for pharmaceutical companies to differentiate their products, driving market growth through increased adoption and market penetration.

Restraint Factors Of Semaglutide Market

Competition from Existing Diabetes Treatments Restricts Market Growth

Competition from existing diabetes treatments poses a notable challenge to market growth within the pharmaceutical industry. Established medications for managing type 2 diabetes, including insulin therapies, sulfonylureas, and DPP-4 inhibitors, represent formidable competitors to newer entrants like Semaglutide. These treatments have well-established efficacy profiles, extensive clinical data, and familiarity among healthcare providers and patients. Moreover, generic versions of some diabetes medications offer cost-effective alternatives, further intensifying competition. In response, pharmaceutical companies developing innovative therapies like Semaglutide must demonstrate significant clinical benefits, such as improved glycaemic control, weight reduction, or reduced cardiovascular risk, to differentiate their products. Additionally, strategic pricing, marketing efforts, and partnerships with healthcare providers are essential for overcoming competition and expanding market share. Despite these challenges, the growing prevalence of diabetes and the need for more effective treatment options provide opportunities for novel therapies like Semaglutide to carve out their niche and drive market growth over time.

Impact of COVID-19 on the S...

In Spain, childhood obesity reaches its highest rate among children aged six to nine years, affecting one in five. In contrast, the lowest rates are observed in the two to five-year-old group, with an estimated prevalence ranging from 2 percent to 10 percent.

In 2024, around 59 percent of adults in Mexico stated that they believed obesity was the biggest health problem facing people in their country, while in Japan only eight percent of adults stated the same. This statistic illustrates the percentage of adults worldwide who stated that obesity was the biggest health problem facing people in their country in 2024.

This statistic shows share of people who were overweight or obese in Sweden in 2022, by age group. The age group with the highest share of overweight and obese people was from 45 to 64 years, with **** percent of this age group classed as overweight and **** percent obese.

In 2024, the mean average weight reported by men was 195 pounds, while the mean average weight for women was 164 pounds. This statistic shows the mean self-reported weight among U.S. adults from 1990 to 2024, by gender, in pounds.